Inactivation of the AIDS-causing retrovirus and other human viruses in antihemophilic plasma protein preparations by pasteurization.
Heat treatment at 60 degrees C for 10 h in solution (pasteurization) was introduced into the manufacturing process of antihemophilic cryoprecipitate (AHC) and factor VIII concentrates (F VIII) to reduce the risk of transmission of hepatitis to hemophiliacs. Since the acquired immunodeficiency syndrome (AIDS) may also be transmitted to hemophiliacs by antihemophilic plasma protein preparations, we have investigated inactivation of the AIDS virus HTLV III by pasteurization in AHC or F VIII and included in this study cytomegalovirus (CMV), Epstein-Barr virus (EBV), herpes simplex virus (HSV), poliovirus and vaccinia virus. Each of these viruses was efficiently inactivated by pasteurization although considerable differences were observed between the different viruses HTLV III was rapidly inactivated, becoming nondetectable within 30-60 min. Our findings indicate that pasteurized AHC or F VIII should have a high margin of safety regarding the transmission of AIDS or any other infectious disease caused by viruses such as those tested.
D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control*; D001798:Blood Proteins / Q000627:therapeutic use*; D003587:Cytomegalovirus / Q000502:physiology; D017977:Deltaretrovirus / Q000502:physiology*; D005169:Factor VIII / Q000627:therapeutic use*; D004854:Herpesvirus 4, Human / Q000502:physiology; D006358:Hot Temperature; D006801:Humans; D017955:Poliovirus / Q000502:physiology; D018139:Simplexvirus / Q000502:physiology; D014616:Vaccinia virus / Q000502:physiology; D014841:von Willebrand Factor / Q000032:analysis / Q000627:therapeutic use*
D001798:Blood Proteins; D014841:von Willebrand Factor; D005169:Factor VIII